Agendia BV, a Dutch breast cancer testing company, has moved its U.S. headquarters to Irvine from Huntington Beach.
Agendia now is in a 17,000-square-foot building at 22 Morgan near Bake Parkway and Jeronimo Road in the Irvine Spectrum that includes a laboratory and corporate offices. The company has about 50 workers locally and 90 in all.
Growth in Agendia’s testing led to its move, said Bernhard Sixt, Agendia’s chief executive. Agendia makes MammaPrint, a test that assesses 70 genes and is designed to predict the reoccurrence of breast cancer in women who have been treated for the disease.
Agendia’s new building has laboratory capacity that could be “easily quadrupled” if necessary, according to Sixt.
The company was started in 2003 and received Food and Drug Administration approval for MammaPrint in 2007.
Sixt declined to say how much revenue privately held Agendia has.
Investors include ING Groep NV and several Dutch venture capital firms. Agendia raised $23 million in a venture capital funding round last fall.
